Literature DB >> 24418750

Mycophenolate mofetil vs. methotrexate for the prevention of graft-versus-host-disease--systematic review and meta-analysis.

Ron Ram1, Moshe Yeshurun2, Liat Vidal2, Ofer Shpilberg2, Anat Gafter-Gvili2.   

Abstract

We performed a systematic review and meta-analysis of all trials comparing MMF and methotrexate as GVHD prophylaxis. Our search yielded 11 studies; 3 were randomized-control trials (RCTs). While the incidence of grades 2-4 acute GVHD was comparable, the incidence of grades 3 and 4 acute GVHD was higher in patients given MMF (RR 1.61; 95% CI 1.18-2.30). Incidence of mucositis was lower (RR 0.35; 95% CI 0.25-0.49) and time to engraftment was shorter (mean difference (-3.6); 95% CI -5.5 to -1.7) in patients given MMF. All other analyzed transplantation outcomes were comparable. We conclude that MMF, compared to methotrexate, is associated with increased severity of acute GVHD. Robustness of these results is hampered by the small number of RCTs.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Allogeneic transplantation; Graft-versus-host disease; Methotrexate; Mycopheolate

Mesh：

Substances：

Year:  2013        PMID： 24418750     DOI： 10.1016/j.leukres.2013.12.012

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  11 in total

1.  Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.

Authors:  Corey Cutler; Brent Logan; Ryotaro Nakamura; Laura Johnston; Sung Choi; David Porter; William J Hogan; Marcelo Pasquini; Margaret L MacMillan; Jack W Hsu; Edmund K Waller; Stephan Grupp; Philip McCarthy; Juan Wu; Zhen-Huan Hu; Shelly L Carter; Mary M Horowitz; Joseph H Antin
Journal:  Blood       Date:  2014-06-30       Impact factor: 22.113

2.  Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies.

Authors:  Nobuhiko Imahashi; Seitaro Terakura; Eisei Kondo; Shinichi Kako; Naoyuki Uchida; Hikaru Kobayashi; Yoshihiro Inamoto; Hitoshi Sakai; Masatsugu Tanaka; Jun Ishikawa; Yasuji Kozai; Ken-Ichi Matsuoka; Takafumi Kimura; Takahiro Fukuda; Yoshiko Atsuta; Junya Kanda
Journal:  Bone Marrow Transplant       Date:  2020-05-21       Impact factor: 5.483

3.  Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.

Authors:  Saurabh Chhabra; Ying Liu; Michael T Hemmer; Luciano Costa; Joseph A Pidala; Daniel R Couriel; Amin M Alousi; Navneet S Majhail; Robert K Stuart; Dennis Kim; Olle Ringden; Alvaro Urbano-Ispizua; Ayman Saad; Bipin N Savani; Brenda Cooper; David I Marks; Gerard Socie; Harry C Schouten; Helene Schoemans; Hisham Abdel-Azim; Jean Yared; Jean-Yves Cahn; John Wagner; Joseph H Antin; Leo F Verdonck; Leslie Lehmann; Mahmoud D Aljurf; Margaret L MacMillan; Mark R Litzow; Melhem M Solh; Muna Qayed; Peiman Hematti; Rammurti T Kamble; Ravi Vij; Robert J Hayashi; Robert P Gale; Rodrigo Martino; Sachiko Seo; Shahrukh K Hashmi; Taiga Nishihori; Takanori Teshima; Usama Gergis; Yoshihiro Inamoto; Stephen R Spellman; Mukta Arora; Betty K Hamilton
Journal:  Biol Blood Marrow Transplant       Date:  2018-08-25       Impact factor: 5.742

4.  Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation.

Authors:  Mary Eapen; Brent R Logan; Mary M Horowitz; Xiaobo Zhong; Miguel-Angel Perales; Stephanie J Lee; Vanderson Rocha; Robert J Soiffer; Richard E Champlin
Journal:  J Clin Oncol       Date:  2014-12-22       Impact factor: 44.544

5.  Reduced-dose methotrexate in combination with tacrolimus was associated with rapid engraftment and recovery from oral mucositis without affecting the incidence of GVHD.

Authors:  Toshihiro Matsukawa; Daigo Hashimoto; Junichi Sugita; Seitarou Nakazawa; Takae Matsushita; Haruhiko Kashiwazaki; Hideki Goto; Masahiro Onozawa; Kaoru Kahata; Katsuya Fujimoto; Tomoyuki Endo; Takeshi Kondo; Satoshi Hashino; Yutaka Yamazaki; Takanori Teshima
Journal:  Int J Hematol       Date:  2016-04-27       Impact factor: 2.490

6.  Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT.

Authors:  V Ratanatharathorn; A Deol; L Ayash; S Cronin; D Bhutani; L G Lum; M Abidi; M Ventimiglia; K Mellert; J P Uberti
Journal:  Bone Marrow Transplant       Date:  2014-10-06       Impact factor: 5.483

7.  Conformal Nanoencapsulation of Allogeneic T Cells Mitigates Graft-versus-Host Disease and Retains Graft-versus-Leukemia Activity.

Authors:  Shuting Zhao; Lingling Zhang; Jianfeng Han; Jianhong Chu; Hai Wang; Xilin Chen; Youwei Wang; Norm Tun; Lanchun Lu; Xue-Feng Bai; Martha Yearsley; Steven Devine; Xiaoming He; Jianhua Yu
Journal:  ACS Nano       Date:  2016-05-31       Impact factor: 15.881

Review 8.  Possible implication of bacterial infection in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Shigeo Fuji; Markus Kapp; Hermann Einsele
Journal:  Front Oncol       Date:  2014-04-24       Impact factor: 6.244

9.  Comparison of non-myeloablative conditioning regimens for lymphoproliferative disorders.

Authors:  S Hong; J Le-Rademacher; A Artz; P L McCarthy; B R Logan; M C Pasquini
Journal:  Bone Marrow Transplant       Date:  2014-12-01       Impact factor: 5.483

10.  Bioengineering of injectable encapsulated aggregates of pluripotent stem cells for therapy of myocardial infarction.

Authors:  Shuting Zhao; Zhaobin Xu; Hai Wang; Benjamin E Reese; Liubov V Gushchina; Meng Jiang; Pranay Agarwal; Jiangsheng Xu; Mingjun Zhang; Rulong Shen; Zhenguo Liu; Noah Weisleder; Xiaoming He
Journal:  Nat Commun       Date:  2016-10-27       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.